Insiders · RNAC

RNAC insider transactions

Cartesian Therapeutics Inc. (RNAC) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for RNAC

• 65d
  SEC Form 4 filed by Hoge Elizabeth

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 65d
  SEC Form 4 filed by Kalayoglu Murat

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 89d
  Director Singer Michael gifted 6,555 units of Common Stock, decreasing direct ownership by 12% to 49,578 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 153d
  President and CEO Brunn Carsten sold $162,077 worth of shares (23,766 units at $6.82), decreasing direct ownership by 7% to 323,530 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 153d
  Chief Financial Officer Davis Blaine sold $72,227 worth of Common Stock (10,591 units at $6.82), decreasing direct ownership by 8% to 121,220 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 153d
  Chief Medical Officer Miljkovic Milos sold $24,367 worth of Common Stock (3,573 units at $6.82), decreasing direct ownership by 6% to 58,820 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Director Desilva Nishan M was granted 2,600 shares, increasing direct ownership by 30% to 11,366 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  President and CEO Brunn Carsten was granted 143,200 shares, increasing direct ownership by 70% to 347,296 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Director Malik Kemal was granted 2,600 units of Common Stock, increasing direct ownership by 30% to 11,133 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Chief Medical Officer Miljkovic Milos was granted 27,000 units of Common Stock, increasing direct ownership by 76% to 62,393 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Chief Accounting Officer Seymour June Ann was granted 6,500 units of Common Stock (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Director Zenner Patrick J was granted 2,600 shares, increasing direct ownership by 25% to 12,974 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Chief Financial Officer Davis Blaine was granted 37,000 units of Common Stock, increasing direct ownership by 39% to 131,811 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Director Barabe Timothy C was granted 2,600 shares, increasing direct ownership by 5% to 56,966 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Chief Operations Officer English Emily was granted 24,000 units of Common Stock, increasing direct ownership by 34% to 94,226 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Director Singer Michael was granted 2,600 units of Common Stock, increasing direct ownership by 5% to 56,133 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Director Springer Timothy A was granted 2,600 shares, increasing direct ownership by 0.03% to 8,646,285 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 155d
  Director Kalayoglu Murat was granted 2,600 units of Common Stock, increasing direct ownership by 0.51% to 511,577 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 159d
  Chief Operations Officer English Emily exercised 7,500 units of Common Stock at a strike of $3.30, increasing direct ownership by 12% to 70,226 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 174d
  Director Bot Adrian Ion was granted 5,800 units of Common Stock (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 174d
  SEC Form 3 filed by new insider Bot Adrian Ion

  3 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 184d
  Director Barabe Timothy C bought $205,797 worth of shares (30,000 units at $6.86), increasing direct ownership by 123% to 54,366 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 190d
  SEC Form 4 filed by Cartesian Therapeutics Inc.

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 203d
  Director Singer Michael gifted 20,000 units of Common Stock, decreasing direct ownership by 27% to 53,533 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 225d
  SEC Form 4 filed by Chief Accounting Officer Seymour June Ann

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 225d
  SEC Form 3 filed by new insider Seymour June Ann

  3 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 392d
  Chief Operations Officer English Emily exercised 7,500 units of Common Stock at a strike of $3.30, increasing direct ownership by 16% to 55,226 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 420d
  Chief Operations Officer English Emily exercised 7,500 units of Common Stock at a strike of $3.30, increasing direct ownership by 19% to 47,726 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 425d
  Director Springer Timothy A bought $1,522,517 worth of shares (149,075 units at $10.21), increasing direct ownership by 0.26% to 8,643,685 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 447d
  Director Springer Timothy A bought $1,371,154 worth of shares (89,863 units at $15.26), increasing direct ownership by 1% to 8,621,325 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 511d
  Director Springer Timothy A bought $366,354 worth of shares (20,967 units at $17.47), increasing direct ownership by 0.25% to 8,531,462 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 513d
  Chief Scientific Officer Jewell Christopher M exercised 9,000 units of Common Stock at a strike of $3.23, increasing direct ownership by 17% to 62,490 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 519d
  Chief Technology Officer Kurtoglu Metin sold $81,790 worth of Common Stock (4,875 units at $16.78), decreasing direct ownership by 7% to 62,258 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 519d
  Chief Medical Officer Miljkovic Milos sold $31,542 worth of Common Stock (1,880 units at $16.78), decreasing direct ownership by 5% to 35,393 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 519d
  Chief Scientific Officer Jewell Christopher M sold $42,783 worth of Common Stock (2,550 units at $16.78), decreasing direct ownership by 5% to 53,490 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 519d
  Chief Operations Officer English Emily sold $30,149 worth of Common Stock (1,797 units at $16.78), decreasing direct ownership by 4% to 40,226 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 519d
  President and CEO Brunn Carsten sold $289,764 worth of shares (17,271 units at $16.78), decreasing direct ownership by 8% to 204,096 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 519d
  Chief Financial Officer Davis Blaine sold $134,036 worth of Common Stock (7,989 units at $16.78), decreasing direct ownership by 8% to 94,811 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Chief Scientific Officer Jewell Christopher M was granted 16,100 units of Common Stock, increasing direct ownership by 40% to 56,040 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  President and CEO Brunn Carsten was granted 57,500 shares, increasing direct ownership by 35% to 221,367 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Chief Operations Officer English Emily was granted 16,100 units of Common Stock, increasing direct ownership by 62% to 42,023 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Chief Financial Officer Davis Blaine was granted 22,000 units of Common Stock, increasing direct ownership by 27% to 102,800 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Springer Timothy A was granted 2,600 shares, increasing direct ownership by 0.03% to 8,510,495 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Chief Medical Officer Miljkovic Milos was granted 19,000 units of Common Stock, increasing direct ownership by 104% to 37,273 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Barabe Timothy C was granted 2,600 shares, increasing direct ownership by 12% to 24,366 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Zenner Patrick J was granted 2,600 shares, increasing direct ownership by 33% to 10,374 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Malik Kemal was granted 2,600 units of Common Stock, increasing direct ownership by 44% to 8,533 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Kalayoglu Murat was granted 2,600 units of Common Stock, increasing direct ownership by 0.51% to 508,977 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Chief Technology Officer Kurtoglu Metin was granted 16,100 units of Common Stock, increasing direct ownership by 32% to 67,133 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Singer Michael was granted 2,600 units of Common Stock, increasing direct ownership by 4% to 73,533 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Cox Carrie Smith was granted 2,600 units of Common Stock, increasing direct ownership by 20% to 15,629 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 520d
  Director Desilva Nishan M was granted 2,600 shares, increasing direct ownership by 42% to 8,766 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 527d
  Director Singer Michael gifted 20,000 units of Common Stock, decreasing direct ownership by 22% to 70,933 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 527d
  SVP, Head of Manufacturing English Emily exercised 7,650 units of Common Stock at a strike of $3.30, increasing direct ownership by 42% to 25,923 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 534d
  Director Springer Timothy A bought $965,021 worth of shares (52,189 units at $18.49), increasing direct ownership by 0.62% to 8,507,895 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 546d
  Chief Technology Officer Kurtoglu Metin exercised 13,664 units of Common Stock at a strike of $1.41 and sold $345,134 worth of Common Stock (13,664 units at $25.26) (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 566d
  Chief Technology Officer Kurtoglu Metin exercised 38,689 units of Common Stock at a strike of $1.41 and sold $649,030 worth of Common Stock (38,689 units at $16.78) (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 566d
  Director Singer Michael gifted 28,821 units of Common Stock, decreasing direct ownership by 24% to 90,933 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 566d
  Chief Scientific Officer Jewell Christopher M exercised 14,000 units of Common Stock at a strike of $3.23, increasing direct ownership by 54% to 39,940 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
• 569d
  Director Springer Timothy A bought $7,373,527 worth of shares (431,940 units at $17.07), increasing direct ownership by 5% to 8,455,706 units (SEC Form 4)

  4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)